JP2021521275A5 - - Google Patents

Info

Publication number
JP2021521275A5
JP2021521275A5 JP2021504593A JP2021504593A JP2021521275A5 JP 2021521275 A5 JP2021521275 A5 JP 2021521275A5 JP 2021504593 A JP2021504593 A JP 2021504593A JP 2021504593 A JP2021504593 A JP 2021504593A JP 2021521275 A5 JP2021521275 A5 JP 2021521275A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
binding protein
sequence shown
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021504593A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021521275A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/053040 external-priority patent/WO2019198051A2/en
Publication of JP2021521275A publication Critical patent/JP2021521275A/ja
Publication of JP2021521275A5 publication Critical patent/JP2021521275A5/ja
Priority to JP2025006634A priority Critical patent/JP2025081307A/ja
Pending legal-status Critical Current

Links

JP2021504593A 2018-04-13 2019-04-12 Ｎｋ細胞結合抗体融合構築物 Pending JP2021521275A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025006634A JP2025081307A (ja) 2018-04-13 2025-01-17 Ｎｋ細胞結合抗体融合構築物

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP18167385 2018-04-13
EP18167385.6 2018-04-13
EP18167384 2018-04-13
EP18167384.9 2018-04-13
EP18190662 2018-08-24
EP18190662.9 2018-08-24
EP18190661 2018-08-24
EP18190661.1 2018-08-24
PCT/IB2019/053040 WO2019198051A2 (en) 2018-04-13 2019-04-12 Nk cell engaging antibody fusion constructs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025006634A Division JP2025081307A (ja) 2018-04-13 2025-01-17 Ｎｋ細胞結合抗体融合構築物

Publications (2)

Publication Number Publication Date
JP2021521275A JP2021521275A (ja) 2021-08-26
JP2021521275A5 true JP2021521275A5 (enExample) 2022-04-20

Family

ID=66625219

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021504593A Pending JP2021521275A (ja) 2018-04-13 2019-04-12 Ｎｋ細胞結合抗体融合構築物
JP2025006634A Pending JP2025081307A (ja) 2018-04-13 2025-01-17 Ｎｋ細胞結合抗体融合構築物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025006634A Pending JP2025081307A (ja) 2018-04-13 2025-01-17 Ｎｋ細胞結合抗体融合構築物

Country Status (21)

Country Link
US (3) US11001633B2 (enExample)
EP (1) EP3774914A2 (enExample)
JP (2) JP2021521275A (enExample)
KR (1) KR20200143436A (enExample)
CN (3) CN113817066A (enExample)
AU (2) AU2019252970A1 (enExample)
BR (1) BR112020020828A2 (enExample)
CA (1) CA3095373A1 (enExample)
CL (2) CL2020002625A1 (enExample)
CO (1) CO2020014167A2 (enExample)
CR (1) CR20200549A (enExample)
IL (1) IL277925A (enExample)
MA (1) MA52227A (enExample)
MX (1) MX2020010728A (enExample)
PE (1) PE20201346A1 (enExample)
PH (1) PH12020551664B1 (enExample)
RU (1) RU2022105827A (enExample)
SG (1) SG11202010064QA (enExample)
TW (1) TW202012441A (enExample)
WO (1) WO2019198051A2 (enExample)
ZA (1) ZA202006325B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220396635A1 (en) * 2019-09-25 2022-12-15 Universität Stuttgart Trivalent binding molecules
US20230227559A1 (en) * 2019-12-10 2023-07-20 Institut Pasteur New antibody blocking human fcgriiia and fcgriiib
GB201919058D0 (en) * 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibodies
AU2020414409A1 (en) 2019-12-27 2022-06-16 Affimed Gmbh Method for the production of bispecific FcyRIIl x CD30 antibody construct
WO2022002033A1 (zh) * 2020-06-30 2022-01-06 和铂医药(上海)有限责任公司 具有H2L2与HCAb结构的结合蛋白
CN116368154A (zh) 2020-10-08 2023-06-30 阿菲姆德股份有限公司 三特异性结合剂
JP2023548538A (ja) * 2020-11-08 2023-11-17 シージェン インコーポレイテッド 併用療法
WO2022120033A1 (en) * 2020-12-03 2022-06-09 Amgen Inc. Immunoglobuline constructs with multiple binding domains
CA3209579A1 (en) * 2021-01-27 2022-08-04 Innovent Biologics (Suzhou) Co., Ltd. Single-domain antibody against cd16a and use thereof
WO2022232503A1 (en) 2021-04-30 2022-11-03 Genentech, Inc. Therapeutic and diagnostic methods and compositions for cancer
AU2022320948A1 (en) 2021-07-30 2024-01-18 Affimed Gmbh Duplexbodies
WO2023006082A1 (zh) * 2021-07-30 2023-02-02 启愈生物技术(上海)有限公司 抗原靶向、抗cd16a和免疫效应细胞激活三功能融合蛋白及其应用
CN113929785B (zh) * 2021-09-10 2023-05-23 钦元再生医学(珠海)有限公司 一种可自分泌pd1-trem2双特异性抗体的嵌合抗原受体免疫细胞及其应用
AU2022353119A1 (en) * 2021-09-24 2024-04-11 Synergy Imt, Inc. Composition of recombinant antigen binding molecules and method of making and using thereof
AU2022381918A1 (en) 2021-11-03 2024-06-13 Affimed Gmbh Bispecific cd16a binders
JP2024543822A (ja) 2021-11-03 2024-11-26 アフィメド ゲーエムベーハー 二重特異性ｃｄ１６ａバインダー
CN116284385A (zh) * 2021-12-07 2023-06-23 信达细胞制药(苏州)有限公司 靶向bcma的p329g抗体及其与嵌合抗原受体细胞的组合和应用
CN114349869B (zh) * 2021-12-20 2023-09-26 上海恩凯细胞技术有限公司 一种双特异性的nk细胞激动剂及制备方法和应用
JP2025528087A (ja) * 2022-08-05 2025-08-26 チマゲン・バイオサイエンシズ，リミテッド 二量体化可能な腫瘍抗原及び免疫刺激抗原を標的とする多重特異性抗体
CA3267339A1 (en) * 2022-09-14 2024-03-21 Otsuka Pharmaceutical Co., Ltd. PD-1 AGONIST ANTIBODIES
CN120641128A (zh) * 2023-02-06 2025-09-12 乐普创一生物科技（上海）有限公司 抗cd16a抗体及其用途
WO2024186092A1 (ko) * 2023-03-06 2024-09-12 주식회사 드노보 바이오테라퓨틱스 신규한 항-cd16 항체 및 이의 용도
WO2025257588A1 (en) * 2024-06-10 2025-12-18 Affimed Gmbh Cd16a/tumor antigen polyspecific binder for use in the treatment of immune checkpoint inhibitor resistance
WO2026087751A1 (en) 2024-10-24 2026-04-30 Affimed Gmbh Combination of immune cell engager and nk cell products

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3720353B2 (ja) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル 多価および多重特異性の結合タンパク質、それらの製造および使用
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
CA2438682A1 (en) 2001-02-20 2002-08-29 Zymogenetics, Inc. Antibodies that bind both bcma and taci
GB0510790D0 (en) * 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
KR101589785B1 (ko) 2009-03-10 2016-01-28 바이오젠 엠에이 인코포레이티드 항-ｂｃｍａ 항체
LT2361936T (lt) * 2010-02-25 2016-09-12 Affimed Gmbh Antigeną rišanti molekulė ir jos panaudojimas
SI3415531T1 (sl) 2011-05-27 2023-12-29 Glaxo Group Limited Bcma (cd269/tnfrsf17) - vezni proteini
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
US9676857B2 (en) 2012-03-16 2017-06-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Soluble engineered monomeric Fc
US11180572B2 (en) * 2012-07-06 2021-11-23 Genmab B.V. Dimeric protein with triple mutations
ES2937015T3 (es) 2012-11-01 2023-03-23 Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft Anticuerpo contra CD269 (BCMA)
US9963513B2 (en) 2013-02-05 2018-05-08 Engmab Sàrl Method for the selection of antibodies against BCMA
AR095374A1 (es) 2013-03-15 2015-10-14 Amgen Res Munich Gmbh Moléculas de unión para bcma y cd3
WO2014144357A1 (en) * 2013-03-15 2014-09-18 Merck Patent Gmbh Tetravalent bispecific antibodies
US20160326249A1 (en) * 2014-01-15 2016-11-10 Zymeworks Inc. Bi-specific cd3 and cd19 antigen-binding constructs
DK3237005T3 (en) * 2014-12-22 2024-11-18 Systimmune Inc Bispecific tetravalent antibodies and methods of making and using thereof
CA2973720A1 (en) * 2015-01-14 2016-07-21 Compass Therapeutics Llc Multispecific immunomodulatory antigen-binding constructs
EP3091031A1 (en) * 2015-05-04 2016-11-09 Affimed GmbH Combination of a bispecific antibody with an immune modulating molecule for the treatment of a tumor
PT3292153T (pt) * 2015-05-04 2019-11-05 Affimed Gmbh Combinação de um anticorpo cd30xcd16a com um anticorpo antagonístico anti-pd-1 para terapia
WO2016207278A1 (en) * 2015-06-23 2016-12-29 Innate Pharma Multispecific nk engager proteins
WO2017031104A1 (en) * 2015-08-17 2017-02-23 Janssen Pharmaceutica Nv Anti-bcma antibodies, bispecific antigen binding molecules that bind bcma and cd3, and uses thereof
EP3156417A1 (en) * 2015-10-13 2017-04-19 Affimed GmbH Multivalent fv antibodies
CN105367660B (zh) * 2015-12-22 2018-12-21 深圳市北科生物科技有限公司 一种抗cd16a抗原和抗muc1抗原的双特异性抗体
CN106632681B (zh) * 2016-10-11 2017-11-14 北京东方百泰生物科技有限公司 抗egfr和抗cd3双特异抗体及其应用
CA3051062C (en) * 2017-02-28 2023-09-26 Affimed Gmbh Tandem diabody for cd16a-directed nk-cell engagement

Similar Documents

Publication Publication Date Title
JP7853939B2 (ja) 二重特異性チェックポイント阻害剤抗体
KR102607909B1 (ko) 항-cd28 조성물
RU2022105827A (ru) Слитые конструкции антител для вовлечения nk-клеток
JP7450684B2 (ja) 制約されたｃｄ３結合を有する多重特異性ポリペプチド構築物およびそれを使用する方法
US11932675B2 (en) PD-1 targeted IL-15/IL-15Rα Fc fusion proteins with improved properties
JP2025061672A (ja) Ｅｎｐｐ３およびｃｄ３に結合するヘテロ二量体抗体
JP2018525382A5 (enExample)
IL268836B1 (en) Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
JP7080219B2 (ja) 共刺激受容体およびチェックポイント受容体に連結する二重特異性免疫調節抗体
JP2023159379A (ja) Ｐｄ－１とｖｅｇｆを標的とした四価二重特異性抗体、その製造方法および用途
JP2023550419A5 (enExample)
JP2025504795A5 (enExample)
US20250043001A1 (en) Anti-cd28 compositions
CN121311507A (zh) 抗cd28 x抗trop2抗体
US20250122299A1 (en) ANTI-CD20 x ANTI-CD28 COMBINATION THERAPIES
US20250084186A1 (en) Anti-cd28 x anti-enpp3 antibodies
WO2025201240A1 (en) Antibodies targeting cd3, cd28, and pd-l1 and uses thereof
CN121311245A (zh) 用于治疗多发性骨髓瘤的方法
CA3212336A1 (en) Methods for treating multiple myeloma
WO2025090973A2 (en) Anti-trop2 x anti-pdl1 x anti-cd28 antibodies
CN116547306A (zh) 抗cd28和/或抗b7h3组合物
RU2023101035A (ru) Антитела к pd-1 и слитые белки
RU2020134591A (ru) Слитые конструкции антител для вовлечения nk-клеток
HK40047548A (en) Heterodimeric antibodies that bind fibroblast activation protein